Loading...
Loading...
EPIX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 10.5M |
| Operating I/L | -10.5M |
| Other Income/Expense | 1.5M |
| Interest Income | 0.0M |
| Pretax | -9.0M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -9.0M |
ESSA Pharma Inc. is a clinical stage pharmaceutical company specializing in developing novel therapies for prostate cancer treatment. Its primary focus is on the development of EPI-7386, an oral candidate currently in Phase I clinical study for metastatic castration-resistant prostate cancer. The company generates revenue through collaboration agreements with industry leaders such as Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc., leveraging its expertise and proprietary therapies to advance the treatment of prostate cancer.
